Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Surgery history, no liver metastases, and lower CA19-9 levels predict longer survival for advanced pancreatic cancer patients on programmed cell death protein-1 (PD-1) inhibitors. These factors improve outcomes in this challenging cancer therapy.
Area Of Science
- Oncology
- Immunotherapy
- Cancer Prognostics
Background
- Programmed cell death protein-1 (PD-1) inhibitors represent a key immunotherapy for cancer treatment.
- Prognostic challenges remain significant for patients with advanced pancreatic cancer (PC) receiving PD-1 inhibitors.
Purpose Of The Study
- To identify prognostic factors influencing outcomes in advanced pancreatic cancer patients treated with PD-1 inhibitors.
- To evaluate the efficacy of PD-1 inhibitor therapy based on patient characteristics and treatment history.
Main Methods
- Retrospective analysis of 126 advanced pancreatic cancer patients treated with PD-1 inhibitors from 2015-2022.
- Kaplan-Meier and Cox proportional hazards models were used to assess prognostic factors.
- Statistical significance was determined using a p-value < 0.05.
Main Results
- Median overall survival (mOS) was 12.1 months and median progression-free survival (mPFS) was 4.6 months.
- Significant predictors for mOS included prior surgery (44.2 vs. 10 months), absence of liver metastases (44.2 vs. 6.4 months), and baseline CA19-9 ≤ 216.15 U/ml (18.5 vs. 9.2 months).
- Histologic differentiation (5.5 vs. 3.2 months) and first-line PD-1 inhibitor use (5.1 vs. 1.5 months) were key predictors for mPFS.
Conclusions
- History of surgery, absence of liver metastases, baseline CA19-9 levels, and intermediate/high histologic differentiation are potential predictors of PD-1 inhibitor efficacy in advanced PC.
- These findings suggest potential biomarkers for patient selection and treatment strategy optimization.
- Further validation in prospective clinical trials is warranted.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
